文章摘要
徐婧熙,程晓昱,葛岚.参松养心胶囊治疗慢性心力衰竭合并室性早搏疗效和安全性的Meta分析[J].安徽医药,2018,22(1):122-126.
参松养心胶囊治疗慢性心力衰竭合并室性早搏疗效和安全性的Meta分析
Clinical efficacy and safety of Shensong Yangxin Capsule for treating chronic heart failure patients with premature ventricular beats:a meta-analysis
投稿时间:2016-09-17  
DOI:
中文关键词: 慢性心力衰竭  室性早搏  参松养心胶囊  Meta分析
英文关键词: 
基金项目:安徽卫生厅中医药科研计划课题(2014ZY04) 作者简介:徐婧熙,女,硕士研究生
作者单位
徐婧熙 安徽中医药大学研究生院,安徽 合肥 230012 
程晓昱 安徽中医药大学第一附属医院干部心内科,安徽 合肥 230038 
葛岚 安徽中医药大学第一附属医院干部心内科,安徽 合肥 230038 
摘要点击次数: 813
全文下载次数: 188
中文摘要:
      目的 评价参松养心胶囊治疗慢性心力衰竭(CHF)合并室性早搏的疗效及安全性。方法 系统检索CNKI数据库、CBM数据库、万方数据库、Pubmed数据库、Cochrane Library数据库、Embase数据库,筛选出参松养心胶囊治疗CHF合并室性早搏的随机对照试验(RCT)。运用Cochrane中心提供的RevMan5.3软件进行文献相关风险评估及Meta分析。结果 共检索到有关参松养心胶囊的文献1 303篇,经过初筛和严格评价,纳入符合标准的文献12篇(改良版Jadad评分≥3分)。其中3项研究表明参松养心胶囊对比西药在减少CHF合并室性早搏患者的24 h室性早搏数量及改善临床症状上有显著疗效[RR=1.19,5%CI(1.07~1.33),P<0.001];另3项研究亦说明参松养心胶囊有助于提高左室射血分数的作用[WMD=5.79,95%CI(4.05~7.52),P<0.000 1]。亦有8项研究证实参松养心胶囊在药物出现不良反应上优于对照组[RR=0.37,5%CI(0.23~0.58),P<0.000 1]。结论 系统的评价了参松养心胶囊治疗CHF合并室性早搏,无论在早搏数量的控制上还是在提高左室射血分数、临床症状等心力衰竭治疗上均安全有效,且优于西药;但由于样本量较少,篇幅及文献质量有限,有待于继续开展临床大样本、多中心的RCT试验以进一步证明。
英文摘要:
      Objective To evaluate the clinical efficacy and safety of Shensong Yangxin capsule for treating chronic heart failure patients with premature ventricular beats. Methods Randomized controlled trials (RCTs) on the clinical efficacy and safety of Shensong Yangxin capsule for chronic heart failure patients with premature ventricular beats were retrieved from CNKI database,CBM database,Wanfang database,Pubmed database,Cochrane Library database,and Embase databases.RevMan5.3 supplied by The Cochrane Center was used for the risk assessment and meta-analysis of the outcomes of included RCTs. Results A total of 1303 articles were collected,twelve studies among which were in line with the inclusion criteria (modified version of the Jadad score ≥3 points).Three studies showed that compared with western medicine,Shensong Yangxin capsule had significant efficacy in reducing the number of premature ventricular beats of the patients and improving the clinical symptoms [RR=1.19,5%CI (1.07-1.33),P<0.001].Another three studies showed that Shensong Yangxin capsule was effective in improving left ventricular ejection fraction [WMD=5.79,5%CI(4.05-7.52),P<0.000 1].Eight studies confirmed that Shensong Yangxin capsule caused fewer side effects than the control group [RR=0.37,5%CI (0.23-0.58),P<0.000 1]. Conclusions The systematic evaluation of Shensong Yangxin capsule in the treatment of chronic heart failure combined with premature ventricular beat shows that Shensong Yangxin capsule is better than western medicine in controlling the number of premature ventricular beats,improving left ventricular ejection fraction and relieving clinical symptoms.But because of the small sample size,limited length of the articles and quality of literature,it is necessary to carry out large-sample,multi-center RCT trials.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮